October 19, 2020 News by Mary Chapman Eli Lilly Aquires Disarm, Will Develop SARM1 Program for Axonal Degeneration Eli Lilly has reached an agreement to acquire Disarm Therapeutics, a biotechnology company developing a new class of disease-modifying treatments for patients with axonal degeneration, including those with multiple sclerosis (MS). In its announcement, Lilly committed to advancing Disarm’s prospective therapies, currently in preclinical development.
October 24, 2019 News by Alejandra Viviescas, PhD SARM1 Inhibitors Protect Neurons from Damage in Mice and Cell Cultures, Results Presented at Neuroscience 2019 Show SARM1 inhibitors are a potential oral treatment to slow disease progression in neurodegenerative diseases like multiple sclerosis (MS), according to preclinical results that show the inhibitors protect nerve cells from damage in mice and cell cultures. Researchers at Disarm Therapeutics presented the findings in a poster titled “…
September 13, 2019 News by Joana Carvalho, PhD #ECTRIMS2019 — Eliminating SARM1 Protects Neurons in Mouse Model of MS Eliminating SARM1, an enzyme that plays a key role in nerve cell degeneration, protects neurons in mice with experimental autoimmune encephalomyelitis (EAE), a condition that mimics the key pathological features of multiple sclerosis (MS) in humans. The preclinical findings were presented by researchers at Disarm Therapeutics in a…
August 29, 2019 News by Joana Carvalho, PhD Role of SARM1 Enzyme, Key Player in Neurodegeneration, Detailed in Studies Two new studies delve into the structure of SARM1, an enzyme that plays a key role in nerve cell degeneration, and are expected to aid the development of targeted therapies for neurodegenerative disorders such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), and peripheral neuropathies. SARM1…
November 8, 2018 News by Patricia Inacio, PhD Blocking Protein Called SARM1 Seen to Protect Nerve Cells from Damage Linked to MS Blocking SARM1, a protein identified as a central mediator of nerve cell degeneration, works to prevent damage to axons — nerve cell fibers essential in cell-to-cell communication — and may be a way of treating neurodegenerative diseases like multiple sclerosis (MS), data from Disarm Therapeutics shows. Specially, genetically deleting…
September 21, 2017 News by Patricia Silva, PhD Disarm Therapeutics to Begin Developing Therapy that Prevents Axonal Degeneration Disarm Therapeutics has completed the first round of financing to develop a compound that prevents axonal degeneration in patients with multiple sclerosis (MS) and other neurodegenerative conditions. The treatment approach is based on an earlier discovery at Washington University in St. Louis, showing that the enzyme SARM1…
December 15, 2015 News by Patricia Silva, PhD MS Nerve Degeneration Triggered by Chain Reaction in Cells Researchers in the United Kingdom recently discovered that a small molecule triggers the destruction of axons, a phenomenon observed in neurodegenerative diseases like multiple sclerosis (MS). The study is titled “Wallerian Degeneration Is Executed by an NMN-SARM1-Dependent Late Ca2+ Influx but Only Modestly Influenced by Mitochondria” and appears in the journal…
